Guanidinoacetate Methyltransferase Deficiency

Mendelian MONDO:0012999 Pathograph 28 Metabolic Disease Inborn error of metabolism

Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive inborn error of creatine biosynthesis caused by biallelic pathogenic variants in GAMT (19p13.3). GAMT catalyzes the final step of endogenous creatine synthesis by methylating guanidinoacetate (GAA) to creatine using S-adenosylmethionine as the methyl donor. Loss of GAMT activity produces systemic and cerebral creatine depletion together with neurotoxic accumulation of guanidinoacetate in biofluids and brain. Clinical manifestations are dominated by early-onset neurodevelopmental impairment with intellectual disability, severe speech delay, epilepsy, behavioral abnormalities, and movement disorders. Presymptomatic treatment with creatine supplementation, ornithine, and dietary arginine restriction substantially improves outcomes, motivating addition to the US Recommended Uniform Screening Panel in January 2023. Birth prevalence is estimated at 0.5 to 2 per million live births.

Ask OpenScientist

Ask a research question about Guanidinoacetate Methyltransferase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
11
Phenotypes
28
Pathograph
1
Genes
8
Treatments
1
Deep Research
⚙

Pathophysiology

5
GAMT molecular function deficiency
Biallelic pathogenic variants in GAMT reduce guanidinoacetate methyltransferase catalytic activity.
hepatocyte link
GAMT link
creatine biosynthetic process link ↓ DECREASED
guanidinoacetate N-methyltransferase activity link ↓ DECREASED
liver link
Downstream
Deficient creatine biosynthesis Reduced GAMT activity blocks conversion of guanidinoacetate to creatine.
Show evidence (1 reference)
PMID:37465909 SUPPORT Human Clinical
"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."
Supports GAMT molecular dysfunction as the initiating defect.
Deficient creatine biosynthesis
Blocked conversion of guanidinoacetate to creatine causes systemic and cerebral creatine depletion, impairing the creatine/phosphocreatine energy shuttle needed for rapid ATP regeneration in high-energy-demand tissues.
neuron link
creatine biosynthetic process link ↓ DECREASED phosphocreatine metabolic process link ↓ DECREASED
brain link
Downstream
Guanidinoacetate neurotoxicity Blocked methylation leaves guanidinoacetate upstream of GAMT to accumulate to neurotoxic levels.
Impaired neuronal energy homeostasis Cerebral creatine depletion compromises the creatine/phosphocreatine ATP-buffering system in brain.
Guanidinoacetate Failure to convert guanidinoacetate to creatine causes elevated guanidinoacetate in biofluids and brain.
Creatine Failure of the final creatine biosynthesis step lowers systemic and cerebral creatine.
Creatine on brain MRS Cerebral creatine depletion is detected as reduced creatine on proton brain MRS.
Creatinine Low creatinine reflects reduced creatine available for spontaneous conversion to creatinine.
Show evidence (1 reference)
PMID:38469086 SUPPORT Human Clinical
"Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders."
Confirms cerebral creatine depletion and GAA accumulation as the dual mechanism of disease.
Guanidinoacetate neurotoxicity
Guanidinoacetate (GAA) accumulates in brain, CSF, blood, and urine due to blocked conversion to creatine. GAA is neurotoxic and may alter inhibitory neurotransmission, compounding the effects of cerebral energy deficiency.
neuron link
gamma-aminobutyric acid signaling pathway link
brain link basal ganglion link
Downstream
Impaired neuronal energy homeostasis Guanidinoacetate toxicity compounds the neuronal energy deficit from cerebral creatine depletion.
Neurodevelopmental and movement disorder expression Guanidinoacetate toxicity contributes to the clinical neurologic phenotype.
Show evidence (2 references)
PMID:38469086 SUPPORT Human Clinical
"Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders."
Confirms GAA accumulation as a contributor to the neurological phenotype.
PMID:35505663 SUPPORT Model Organism
"Along with low creatine levels, guanidinoacetic acid (GAA) toxicity has been implicated in the pathophysiology of the disorder."
Supports GAA toxicity as a distinct pathophysiological mechanism beyond creatine deficiency alone.
Impaired neuronal energy homeostasis
The creatine/phosphocreatine system serves as a critical ATP buffer and energy shuttle in neurons. Creatine deficiency impairs rapid ATP regeneration during fluctuating energy demands, contributing to neurodevelopmental dysfunction, seizure susceptibility, and disrupted neurite outgrowth and neurotransmission.
neuron link
ATP metabolic process link
brain link
Downstream
Neurodevelopmental and movement disorder expression Neuronal energy disruption contributes to developmental, seizure, speech, behavioral, and motor manifestations.
Show evidence (2 references)
PMID:37465909 SUPPORT Human Clinical
"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."
Cerebral creatine deficiency directly implies impaired neuronal energy homeostasis via loss of the creatine/phosphocreatine shuttle.
PMID:35505663 SUPPORT Model Organism
"Creatine deficiency disorders are inborn errors of creatine metabolism, an energy homeostasis molecule."
Explicitly identifies creatine as an energy homeostasis molecule, supporting the energy-deficit mechanism.
Neurodevelopmental and movement disorder expression
Combined cerebral creatine depletion and guanidinoacetate accumulation produce the core neurologic presentation of GAMT deficiency, including developmental impairment, epilepsy, speech disturbance, behavioral features, motor findings, hypotonia, involuntary movements, and basal ganglia abnormalities.
neuron link
brain link basal ganglion link
Downstream
Global developmental delay Developmental delay is part of the core neurodevelopmental expression of GAMT deficiency.
Intellectual disability Intellectual disability is a core clinical result of cerebral creatine depletion and GAA accumulation.
Delayed speech and language development Speech and language delay are prominent neurodevelopmental manifestations.
Absent speech Absent speech represents the severe end of GAMT-associated speech and language impairment.
Seizures Seizures are a core manifestation of the combined creatine-depletion and GAA-toxicity neurologic phenotype.
Behavioral abnormality Behavioral problems are among the dominant clinical domains in GAMT deficiency.
Autism Autistic behavior is a reported subset of GAMT-associated behavioral abnormalities.
Movement abnormality Movement disorder is part of the reported neurologic presentation.
Muscular hypotonia Hypotonia is part of the untreated neurologic presentation.
Involuntary movements Involuntary movements are reported among untreated neurologic features.
Abnormality of the globus pallidus Globus pallidus signal abnormality reflects basal ganglia involvement in GAMT deficiency.
Show evidence (3 references)
PMID:38469086 SUPPORT Human Clinical
"intellectual disability, seizures, speech disturbances and movement disorders."
Directly connects cerebral creatine depletion and GAA accumulation to intellectual disability, seizures, speech disturbance, and movement disorder.
PMID:37465909 SUPPORT Human Clinical
"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."
Supports the untreated neurologic phenotype, including intellectual disability, limited speech, and recurrent seizures.
PMID:19289269 SUPPORT Human Clinical
"The MRI scan shows an increased signal in the globus pallidus,"
Supports basal ganglia involvement as part of the neurologic expression of GAMT deficiency.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Guanidinoacetate Methyltransferase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Musculoskeletal 1
Muscular hypotonia FREQUENT Hypotonia (HP:0001252)
Show evidence (2 references)
PMID:37465909 SUPPORT Human Clinical
"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."
Lists hypotonia as an associated feature of untreated GAMT deficiency.
PMID:36856349 SUPPORT Human Clinical
"Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures, movement disorder, behavioral problems, and hypotonia."
Confirms hypotonia among the symptom spectrum.
Nervous System 10
Global developmental delay VERY_FREQUENT Global developmental delay (HP:0001263)
Show evidence (2 references)
PMID:24268530 SUPPORT Human Clinical
"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants"
Quantifies developmental delay at 44/48 (92%) in the landmark GAMT deficiency cohort.
PMID:39006040 SUPPORT Human Clinical
"84% of the cases expressed a form of developmental delay."
Confirms high frequency of developmental delay in a scoping review of 53 cases.
Intellectual disability VERY_FREQUENT Intellectual disability (HP:0001249)
Show evidence (2 references)
PMID:24268530 SUPPORT Human Clinical
"The median age at treatment initiation was 25.5 and 39 months in patients with mild and moderate DD/ID, respectively, and 11 years in patients with severe DD/ID."
Demonstrates correlation between treatment timing and severity of intellectual disability.
PMID:39006040 SUPPORT Human Clinical
"43% of the cases had intellectual disabilities and mental retardation that affected their learning process; most cases required special care."
Supports intellectual disability as a major feature requiring special care.
Delayed speech and language development VERY_FREQUENT Delayed speech and language development (HP:0000750)
Show evidence (2 references)
PMID:19289269 SUPPORT Human Clinical
"The symptoms and signs are reviewed, emphasising that delayed language development is a particular feature."
Identifies delayed language development as a particularly prominent feature of GAMT deficiency.
PMID:24268530 SUPPORT Human Clinical
"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants"
Confirms speech/language delay as one of the most affected domains.
Seizures VERY_FREQUENT Seizure (HP:0001250)
Show evidence (3 references)
PMID:24268530 SUPPORT Human Clinical
"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder in 13."
Quantifies epilepsy at 35/48 (73%) in the landmark cohort.
PMID:39006040 SUPPORT Human Clinical
"68% of the cases developed generalized seizures throughout their life."
Confirms seizures in 68% of cases in the scoping review.
PMID:19289269 SUPPORT Human Clinical
"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."
Lists epileptic seizures among core symptoms of GAMT deficiency.
Behavioral abnormality Atypical behavior (HP:0000708)
Show evidence (2 references)
PMID:19289269 SUPPORT Human Clinical
"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."
Identifies autistic behaviour as a core symptom of GAMT deficiency.
PMID:36856349 SUPPORT Human Clinical
"Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures, movement disorder, behavioral problems, and hypotonia."
Lists behavioral problems among the range of symptoms in creatine deficiency disorders.
Movement abnormality OCCASIONAL Abnormality of movement (HP:0100022)
Show evidence (2 references)
PMID:24268530 SUPPORT Human Clinical
"Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder in 13."
Quantifies movement disorder at 13/48 (27%) in the cohort.
PMID:19289269 SUPPORT Human Clinical
"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."
Confirms movement disorders as a recognized symptom.
Autism OCCASIONAL Autism (HP:0000717)
Show evidence (1 reference)
PMID:19289269 SUPPORT Human Clinical
"Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders."
Identifies autistic behaviour as a recognized symptom.
Abnormality of the globus pallidus OCCASIONAL Abnormal globus pallidus morphology (HP:0002453)
Show evidence (1 reference)
PMID:19289269 SUPPORT Human Clinical
"The MRI scan shows an increased signal in the globus pallidus, and the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine."
Directly describes globus pallidus signal abnormality on MRI.
Absent speech OCCASIONAL Absent speech (HP:0001344)
Show evidence (1 reference)
PMID:37465909 SUPPORT Human Clinical
"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."
Limited speech development in untreated cases can progress to absent speech in severe presentations.
Involuntary movements OCCASIONAL Involuntary movements (HP:0004305)
Show evidence (1 reference)
PMID:37465909 SUPPORT Human Clinical
"Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements."
Explicitly lists involuntary movements among associated features.
🧬

Genetic Associations

1
GAMT pathogenic variants
Autosomal recessive
Show evidence (4 references)
PMID:37465909 SUPPORT Human Clinical
"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."
Confirms pathogenic variants in GAMT as the cause.
PMID:39006040 SUPPORT Human Clinical
"23% of the affected cases were of consanguineous marriages, and 7% had affected relatives."
Quantifies consanguinity as a risk factor in the scoping review.
PMID:39006040 SUPPORT Human Clinical
"Guanidinoacetate methyltransferase deficiency (GAMT) is an autosomal recessive inborn error of metabolism. A condition that results from a pathogenic variant in the GAMT gene that maps to 19p13.3."
Confirms the chromosomal location and autosomal recessive nature.
+ 1 more reference
💊

Treatments

8
Creatine supplementation
Action: Pharmacotherapy NCIT:C15986
Agent: creatine ↗
Oral creatine monohydrate is the cornerstone of therapy, aimed at repleting systemic and cerebral creatine stores. Typical dosing is approximately 400-800 mg/kg/day. Treatment is associated with improvement of cerebral creatine on MRS and clinical symptom stabilization or improvement, though brain creatine may not fully normalize.
Mechanism Target:
BYPASSES Deficient creatine biosynthesis — Oral creatine supplies the downstream product of the blocked GAMT reaction and raises cerebral creatine.
MODULATES Impaired neuronal energy homeostasis — Repleting cerebral creatine supports the creatine/phosphocreatine energy buffer in brain, though brain creatine may remain below control ranges.
Show evidence (3 references)
PMID:24268530 SUPPORT Human Clinical
"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet"
Directly supports creatine supplementation as effective in increasing cerebral creatine.
PMID:24268530 SUPPORT Human Clinical
"Therapy was associated with improvement or stabilization of symptoms in all of the symptomatic cases. The 4 patients treated younger than 9 months had normal or almost normal developmental outcomes."
Demonstrates clinical benefit of early creatine-based therapy.
PMID:38469086 SUPPORT Human Clinical
"Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels."
Confirms creatine supplementation as a treatment component.
Ornithine supplementation
Action: Pharmacotherapy NCIT:C15986
Agent: ornithine ↗
Oral L-ornithine is used as a substrate-reduction strategy to inhibit AGAT activity, thereby reducing guanidinoacetate synthesis. Dosing ranges from 100 to 800 mg/kg/day. Ornithine combined with creatine is more effective than creatine alone at reducing GAA levels.
Mechanism Target:
INHIBITS Guanidinoacetate neurotoxicity — Ornithine supplementation is used as substrate-reduction therapy to lower toxic GAA levels.
Show evidence (3 references)
PMID:24268530 SUPPORT Human Clinical
"Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate and protein/arginine restricted diets."
Confirms ornithine as a standard treatment component.
PMID:24268530 SUPPORT Human Clinical
"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet"
Demonstrates that high-dose ornithine contributes to GAA reduction.
PMID:38469086 SUPPORT Human Clinical
"Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels."
Confirms ornithine's role in reducing toxic GAA levels.
Protein/arginine-restricted diet
Action: dietary intervention MAXO:0000088
Dietary restriction of protein and/or arginine intake reduces the precursor supply for guanidinoacetate synthesis via AGAT, serving as a substrate-reduction approach. This is typically combined with creatine and ornithine supplementation.
Mechanism Target:
INHIBITS Guanidinoacetate neurotoxicity — Restricting protein and arginine reduces precursor flux into guanidinoacetate synthesis.
Show evidence (2 references)
PMID:24268530 SUPPORT Human Clinical
"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet (250 mg/kg/d l-arginine)."
Supports arginine-restricted diet as part of the effective treatment regimen.
PMID:19289269 SUPPORT Human Clinical
"Treatment is based on giving creatine supplementation orally and a low-protein diet with restricted arginine and increased ornithine."
Confirms low-protein, arginine-restricted diet as a standard treatment.
Sodium benzoate therapy
Action: nitrogen scavenger therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: sodium benzoate ↗
Sodium benzoate is used in some treatment protocols to reduce glycine availability, a precursor for guanidinoacetate synthesis. Dosing is approximately 100 mg/kg/day. This reduces the substrate pool available for AGAT, contributing to GAA lowering.
Mechanism Target:
INHIBITS Guanidinoacetate neurotoxicity — Sodium benzoate reduces glycine availability, limiting substrate input into guanidinoacetate production.
Show evidence (1 reference)
PMID:24268530 SUPPORT Human Clinical
"Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate and protein/arginine restricted diets."
Confirms sodium benzoate as a component of treatment protocols.
Newborn screening
Action: disease screening MAXO:0000124
GAMT deficiency screening can be incorporated into existing tandem mass spectrometry newborn screening platforms, detecting elevated guanidinoacetate. The Advisory Committee on Heritable Disorders in Newborns and Children recommended addition to the RUSP, accepted in January 2023. Presymptomatic detection enables early treatment initiation before irreversible neurologic damage.
Target Phenotypes: Global developmental delay ↗ Intellectual disability ↗ Seizure ↗
Show evidence (1 reference)
PMID:37465909 SUPPORT Human Clinical
"the feasibility of screening, the low number of positive results, the relative ease of diagnosis, and the expected benefit of presymptomatic dietary therapy led to a recommendation from the Advisory Committee on Heritable Disorders in Newborns and Children to the Secretary of Health and Human..."
Documents the policy decision to add GAMT deficiency to the RUSP.
Anticonvulsant therapy
Action: antiepileptic drug therapy Ontology label: anticonvulsant agent therapy MAXO:0000167
Agent: anticonvulsant agent ↗
Antiepileptic medications are used to manage seizures, which affect approximately 70% of patients. Seizure improvement is often observed with metabolic treatment (creatine supplementation), sometimes allowing reduction of anticonvulsant medications.
Target Phenotypes: Seizure ↗
Show evidence (1 reference)
PMID:19289269 SUPPORT Human Clinical
"This results in improvement of many of the symptoms, especially of the epileptic seizures and the abnormal movements."
Notes that treatment improves epileptic seizures, implying anticonvulsant management is part of care.
Genetic counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for affected families covers autosomal recessive inheritance, 25% recurrence risk, carrier testing, prenatal diagnosis, and the importance of premarital genetic testing in populations with high consanguinity rates.
Show evidence (2 references)
PMID:39006040 SUPPORT Human Clinical
"Premarital testing of neurogenetic diseases using whole-exome sequencing is probably a future direction, especially in populations with high consanguinity rates."
Supports genetic counseling and carrier testing, particularly in consanguineous populations.
PMID:37465909 SUPPORT Human Clinical
"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene"
Autosomal recessive inheritance necessitates genetic counseling for family planning.
Gene therapy (investigational)
Action: gene therapy MAXO:0001001
AAV-based gene therapy expressing human GAMT in hepatocytes is under preclinical development. In a murine model, liver-directed gene therapy achieved pan-hepatic GAMT expression, marked and sustained reduction of GAA, normalization of plasma creatine, increased cerebral and myocardial creatine, and resolution of behavioral abnormalities. CNS-directed AAV9 approaches are also being investigated.
Mechanism Target:
RESTORES GAMT molecular function deficiency — AAV-mediated GAMT delivery is designed to restore hepatocyte GAMT expression in preclinical models.
RESTORES Deficient creatine biosynthesis — Restoring GAMT expression normalizes plasma creatine and reduces GAA in the mouse model.
Show evidence (2 references)
PMID:35505663 SUPPORT Model Organism
"Serial collection of blood demonstrated a marked early and sustained reduction of GAA with normalization of plasma creatine; urinary GAA levels also markedly declined."
Shows sustained biochemical correction in the gene therapy mouse model.
PMID:35505663 SUPPORT Model Organism
"The terminal time point demonstrated marked improvement in cerebral and myocardial creatine levels. In conjunction with the biochemical findings, treated mice gained weight to nearly match their wild-type littermates, while behavioral studies demonstrated resolution of abnormalities"
Demonstrates improved cerebral/myocardial creatine and resolved behavioral phenotype with gene therapy.
🔬

Biochemical Markers

4
Guanidinoacetate (INCREASED)
Context: Guanidinoacetate (GAA) is markedly elevated in plasma, urine, CSF, and brain in GAMT deficiency. Elevated GAA is the primary diagnostic biomarker and is considered neurotoxic. It can be detected by tandem mass spectrometry in newborn screening programs.
Pathograph Readouts
Readout Of Deficient creatine biosynthesis Positive Diagnostic
Elevated guanidinoacetate reports the blocked GAMT-dependent conversion of guanidinoacetate to creatine.
Readout Of Guanidinoacetate neurotoxicity Positive Monitoring
Plasma, CSF, urine, or brain guanidinoacetate tracks the toxic upstream metabolite burden targeted by substrate-reduction therapy.
Show evidence (3 references)
PMID:37465909 SUPPORT Human Clinical
"Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate."
Confirms neurotoxic GAA accumulation as a defining feature.
PMID:19289269 SUPPORT Human Clinical
"the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine."
Confirms elevated urinary GAA as a diagnostic marker.
PMID:24268530 SUPPORT Human Clinical
"Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet"
Documents elevated baseline plasma/CSF GAA that decreases with treatment.
Creatine (DECREASED)
Context: Creatine is depleted in plasma, urine, CSF, and brain. Cerebral creatine deficiency is detectable by proton magnetic resonance spectroscopy (1H-MRS), which shows absent or markedly decreased creatine peak. Brain creatine may not fully normalize even with long-term treatment.
Pathograph Readouts
Readout Of Deficient creatine biosynthesis Negative Diagnostic
Low creatine reports the missing product of the blocked GAMT-dependent creatine biosynthetic step.
Readout Of Impaired neuronal energy homeostasis Negative Monitoring
Persistently low brain creatine on spectroscopy tracks the residual creatine/phosphocreatine energy-buffer deficit during treatment.
Show evidence (3 references)
PMID:19289269 SUPPORT Human Clinical
"the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine."
Confirms low plasma creatine as a diagnostic finding.
PMID:38469086 SUPPORT Human Clinical
"the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges."
Shows that even with treatment, brain creatine does not normalize, confirming baseline deficiency.
PMID:36856349 SUPPORT Human Clinical
"The diagnosis can be suspected by elevated guanidinoacetate and low creatine levels in body fluids in guanidinoacetate methyltransferase deficiency"
Confirms low creatine in body fluids as a diagnostic marker.
Creatine on brain MRS (DECREASED)
Context: Proton magnetic resonance spectroscopy (1H-MRS) of the brain shows absent or markedly decreased creatine peak, which serves as a non-invasive diagnostic and monitoring tool for cerebral creatine deficiency.
Pathograph Readouts
Readout Of Impaired neuronal energy homeostasis Negative Monitoring
Brain MRS creatine is a tissue-level readout of cerebral creatine repletion and remaining neuronal energy-buffer deficiency.
Show evidence (1 reference)
PMID:38469086 SUPPORT Human Clinical
"the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges."
Confirms decreased brain creatine on MRS that improves but does not normalize with treatment.
Creatinine (DECREASED)
Context: Low urinary creatinine reflects the underlying creatine depletion state. Creatine-to-creatinine ratio in urine helps distinguish GAMT deficiency from creatine transporter deficiency.
{ }

Source YAML

click to show 
name: Guanidinoacetate Methyltransferase Deficiency
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-05-20T06:04:37Z'
synonyms:
- GAMT deficiency
- Cerebral creatine deficiency syndrome type 2
- CCDS2
description: 'Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive inborn error of creatine biosynthesis caused by biallelic pathogenic variants in GAMT (19p13.3). GAMT catalyzes the final step of endogenous creatine synthesis by methylating guanidinoacetate (GAA) to creatine using S-adenosylmethionine as the methyl donor. Loss of GAMT activity produces systemic and cerebral creatine depletion together with neurotoxic accumulation of guanidinoacetate in biofluids and brain. Clinical manifestations are dominated by early-onset neurodevelopmental impairment with intellectual disability, severe speech delay, epilepsy, behavioral abnormalities, and movement disorders. Presymptomatic treatment with creatine supplementation, ornithine, and dietary arginine restriction substantially improves outcomes, motivating addition to the US Recommended Uniform Screening Panel in January 2023. Birth prevalence is estimated at 0.5 to 2 per million live births.

  '
disease_term:
  preferred_term: guanidinoacetate methyltransferase deficiency
  term:
    id: MONDO:0012999
    label: guanidinoacetate methyltransferase deficiency
parents:
- Metabolic Disease
- Inborn error of metabolism
prevalence:
- notes: Birth prevalence is estimated between 0.5 and 2 per million live births. In newborn screening programs, approximately 1 per 100,000 newborns screen positive. Programmatic detection rates include 1 case in 1.4 million screened in Australia, 1 case per 321,305 screened in Utah, and 1 case per 759,246 screened in New York.
progression:
- notes: Newborns may appear asymptomatic at birth due to in utero placental creatine transfer. Symptoms first become noticeable at a mean of approximately 14 months (range 3-24 months). Without newborn screening, mean age at diagnosis is approximately 8.5 years (range 9 months to 25 years). Once significant neurologic impairment develops, treatment benefit is limited, underscoring the critical window for early intervention. The four patients treated before 9 months of age in a landmark cohort had normal or near-normal developmental outcomes.
pathophysiology:
- name: GAMT molecular function deficiency
  description: 'Biallelic pathogenic variants in GAMT reduce guanidinoacetate methyltransferase catalytic activity.

    '
  genes:
  - preferred_term: GAMT
    term:
      id: hgnc:4136
      label: GAMT
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  molecular_functions:
  - preferred_term: guanidinoacetate N-methyltransferase activity
    term:
      id: GO:0008168
      label: methyltransferase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: creatine biosynthetic process
    term:
      id: GO:0006601
      label: creatine biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Supports GAMT molecular dysfunction as the initiating defect.
  downstream:
  - target: Deficient creatine biosynthesis
    causal_link_type: DIRECT
    description: Reduced GAMT activity blocks conversion of guanidinoacetate to creatine.
- name: Deficient creatine biosynthesis
  description: 'Blocked conversion of guanidinoacetate to creatine causes systemic and cerebral creatine depletion, impairing the creatine/phosphocreatine energy shuttle needed for rapid ATP regeneration in high-energy-demand tissues.

    '
  biological_processes:
  - preferred_term: creatine biosynthetic process
    term:
      id: GO:0006601
      label: creatine biosynthetic process
    modifier: DECREASED
  - preferred_term: phosphocreatine metabolic process
    term:
      id: GO:0006603
      label: phosphocreatine metabolic process
    modifier: DECREASED
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  chemical_entities:
  - preferred_term: guanidinoacetate
    term:
      id: CHEBI:131444
      label: guanidinoacetate
    modifier: INCREASED
  - preferred_term: creatine
    term:
      id: CHEBI:16919
      label: creatine
    modifier: DECREASED
  evidence:
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders.
    explanation: Confirms cerebral creatine depletion and GAA accumulation as the dual mechanism of disease.
  downstream:
  - target: Guanidinoacetate neurotoxicity
    causal_link_type: DIRECT
    description: Blocked methylation leaves guanidinoacetate upstream of GAMT to accumulate to neurotoxic levels.
  - target: Impaired neuronal energy homeostasis
    causal_link_type: DIRECT
    description: Cerebral creatine depletion compromises the creatine/phosphocreatine ATP-buffering system in brain.
  - target: Guanidinoacetate
    causal_link_type: DIRECT
    description: Failure to convert guanidinoacetate to creatine causes elevated guanidinoacetate in biofluids and brain.
  - target: Creatine
    causal_link_type: DIRECT
    description: Failure of the final creatine biosynthesis step lowers systemic and cerebral creatine.
  - target: Creatine on brain MRS
    causal_link_type: DIRECT
    description: Cerebral creatine depletion is detected as reduced creatine on proton brain MRS.
  - target: Creatinine
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced creatine availability lowers downstream creatinine generation.
    description: Low creatinine reflects reduced creatine available for spontaneous conversion to creatinine.
- name: Guanidinoacetate neurotoxicity
  description: 'Guanidinoacetate (GAA) accumulates in brain, CSF, blood, and urine due to blocked conversion to creatine. GAA is neurotoxic and may alter inhibitory neurotransmission, compounding the effects of cerebral energy deficiency.

    '
  biological_processes:
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  chemical_entities:
  - preferred_term: guanidinoacetate
    term:
      id: CHEBI:131444
      label: guanidinoacetate
    modifier: INCREASED
  evidence:
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebral creatine depletion and accumulation of guanidinoacetate (GAA) lead to clinical presentation with intellectual disability, seizures, speech disturbances and movement disorders.
    explanation: Confirms GAA accumulation as a contributor to the neurological phenotype.
  - reference: PMID:35505663
    reference_title: "Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Along with low creatine levels, guanidinoacetic acid (GAA) toxicity has been implicated in the pathophysiology of the disorder.
    explanation: Supports GAA toxicity as a distinct pathophysiological mechanism beyond creatine deficiency alone.
  downstream:
  - target: Impaired neuronal energy homeostasis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Elevated guanidinoacetate perturbs neuronal metabolism and inhibitory neurotransmission.
    description: Guanidinoacetate toxicity compounds the neuronal energy deficit from cerebral creatine depletion.
  - target: Neurodevelopmental and movement disorder expression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Elevated guanidinoacetate contributes to neuronal dysfunction alongside cerebral creatine depletion.
    description: Guanidinoacetate toxicity contributes to the clinical neurologic phenotype.
- name: Impaired neuronal energy homeostasis
  description: 'The creatine/phosphocreatine system serves as a critical ATP buffer and energy shuttle in neurons. Creatine deficiency impairs rapid ATP regeneration during fluctuating energy demands, contributing to neurodevelopmental dysfunction, seizure susceptibility, and disrupted neurite outgrowth and neurotransmission.

    '
  biological_processes:
  - preferred_term: ATP metabolic process
    term:
      id: GO:0046034
      label: ATP metabolic process
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  chemical_entities:
  - preferred_term: creatine
    term:
      id: CHEBI:16919
      label: creatine
    modifier: DECREASED
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Cerebral creatine deficiency directly implies impaired neuronal energy homeostasis via loss of the creatine/phosphocreatine shuttle.
  - reference: PMID:35505663
    reference_title: "Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Creatine deficiency disorders are inborn errors of creatine metabolism, an energy homeostasis molecule.
    explanation: Explicitly identifies creatine as an energy homeostasis molecule, supporting the energy-deficit mechanism.
  downstream:
  - target: Neurodevelopmental and movement disorder expression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Loss of the creatine/phosphocreatine ATP buffer affects high-energy neural systems.
    description: Neuronal energy disruption contributes to developmental, seizure, speech, behavioral, and motor manifestations.
- name: Neurodevelopmental and movement disorder expression
  description: 'Combined cerebral creatine depletion and guanidinoacetate accumulation produce the core neurologic presentation of GAMT deficiency, including developmental impairment, epilepsy, speech disturbance, behavioral features, motor findings, hypotonia, involuntary movements, and basal ganglia abnormalities.

    '
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: basal ganglion
    term:
      id: UBERON:0002420
      label: basal ganglion
  evidence:
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: intellectual disability, seizures, speech disturbances and movement disorders.
    explanation: Directly connects cerebral creatine depletion and GAA accumulation to intellectual disability, seizures, speech disturbance, and movement disorder.
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Supports the untreated neurologic phenotype, including intellectual disability, limited speech, and recurrent seizures.
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The MRI scan shows an increased signal in the globus pallidus,
    explanation: Supports basal ganglia involvement as part of the neurologic expression of GAMT deficiency.
  downstream:
  - target: Global developmental delay
    causal_link_type: DIRECT
    description: Developmental delay is part of the core neurodevelopmental expression of GAMT deficiency.
  - target: Intellectual disability
    causal_link_type: DIRECT
    description: Intellectual disability is a core clinical result of cerebral creatine depletion and GAA accumulation.
  - target: Delayed speech and language development
    causal_link_type: DIRECT
    description: Speech and language delay are prominent neurodevelopmental manifestations.
  - target: Absent speech
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Severe limited speech development can progress to absent or extremely limited speech.
    description: Absent speech represents the severe end of GAMT-associated speech and language impairment.
  - target: Seizures
    causal_link_type: DIRECT
    description: Seizures are a core manifestation of the combined creatine-depletion and GAA-toxicity neurologic phenotype.
  - target: Behavioral abnormality
    causal_link_type: DIRECT
    description: Behavioral problems are among the dominant clinical domains in GAMT deficiency.
  - target: Autism
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Autistic features are part of the broader behavioral phenotype.
    description: Autistic behavior is a reported subset of GAMT-associated behavioral abnormalities.
  - target: Movement abnormality
    causal_link_type: DIRECT
    description: Movement disorder is part of the reported neurologic presentation.
  - target: Muscular hypotonia
    causal_link_type: DIRECT
    description: Hypotonia is part of the untreated neurologic presentation.
  - target: Involuntary movements
    causal_link_type: DIRECT
    description: Involuntary movements are reported among untreated neurologic features.
  - target: Abnormality of the globus pallidus
    causal_link_type: DIRECT
    description: Globus pallidus signal abnormality reflects basal ganglia involvement in GAMT deficiency.
phenotypes:
- name: Global developmental delay
  frequency: VERY_FREQUENT
  description: 'Developmental delay/intellectual disability is the most consistent feature, present in 44 of 48 patients (92%) in the landmark cohort, 100% in a 2023 review, and 84% in a 53-case scoping review.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants
    explanation: Quantifies developmental delay at 44/48 (92%) in the landmark GAMT deficiency cohort.
  - reference: PMID:39006040
    reference_title: "Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency: An Analytical Study of a Case Series and a Scoping Review of 53 Cases of Guanidinoacetate N-Methyltransferase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 84% of the cases expressed a form of developmental delay.
    explanation: Confirms high frequency of developmental delay in a scoping review of 53 cases.
- name: Intellectual disability
  frequency: VERY_FREQUENT
  description: 'Intellectual disability ranges from mild to severe and is a hallmark feature. Severity correlates with age at treatment initiation, with patients treated before 9 months achieving normal or near-normal cognitive outcomes.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The median age at treatment initiation was 25.5 and 39 months in patients with mild and moderate DD/ID, respectively, and 11 years in patients with severe DD/ID.
    explanation: Demonstrates correlation between treatment timing and severity of intellectual disability.
  - reference: PMID:39006040
    reference_title: "Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency: An Analytical Study of a Case Series and a Scoping Review of 53 Cases of Guanidinoacetate N-Methyltransferase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 43% of the cases had intellectual disabilities and mental retardation that affected their learning process; most cases required special care.
    explanation: Supports intellectual disability as a major feature requiring special care.
- name: Delayed speech and language development
  frequency: VERY_FREQUENT
  description: 'Speech and language delay is particularly prominent and is often the most affected developmental domain. Many patients have severely limited or absent speech.

    '
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The symptoms and signs are reviewed, emphasising that delayed language development is a particular feature.
    explanation: Identifies delayed language development as a particularly prominent feature of GAMT deficiency.
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants
    explanation: Confirms speech/language delay as one of the most affected domains.
- name: Seizures
  frequency: VERY_FREQUENT
  description: 'Epilepsy occurs in approximately 70-73% of patients. Seizures may reflect both cerebral energy instability and direct GAA effects on inhibitory neurotransmission. Seizure control often improves with creatine supplementation.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder in 13.
    explanation: Quantifies epilepsy at 35/48 (73%) in the landmark cohort.
  - reference: PMID:39006040
    reference_title: "Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency: An Analytical Study of a Case Series and a Scoping Review of 53 Cases of Guanidinoacetate N-Methyltransferase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 68% of the cases developed generalized seizures throughout their life.
    explanation: Confirms seizures in 68% of cases in the scoping review.
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Lists epileptic seizures among core symptoms of GAMT deficiency.
- name: Behavioral abnormality
  description: 'Behavioral disturbances are common and include autistic features, self-mutilation, hyperactivity, and other severe behavioral disorders.

    '
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Identifies autistic behaviour as a core symptom of GAMT deficiency.
  - reference: PMID:36856349
    reference_title: "Creatine Deficiency Disorders: Phenotypes, Genotypes, Diagnosis, and Treatment Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures, movement disorder, behavioral problems, and hypotonia.
    explanation: Lists behavioral problems among the range of symptoms in creatine deficiency disorders.
- name: Movement abnormality
  frequency: OCCASIONAL
  description: 'Movement disorders including dystonia and ataxia occur in approximately 27-30% of patients. In the landmark cohort, movement disorder was documented in 13 of 48 patients.

    '
  phenotype_term:
    preferred_term: Abnormality of movement
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Global developmental delay/intellectual disability (DD/ID) with speech/language delay and behavioral problems as the most affected domains was present in 44 participants, with additional epilepsy present in 35 and movement disorder in 13.
    explanation: Quantifies movement disorder at 13/48 (27%) in the cohort.
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Confirms movement disorders as a recognized symptom.
- name: Muscular hypotonia
  frequency: FREQUENT
  description: 'Hypotonia is a common clinical feature noted in the untreated presentation of GAMT deficiency.

    '
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Lists hypotonia as an associated feature of untreated GAMT deficiency.
  - reference: PMID:36856349
    reference_title: "Creatine Deficiency Disorders: Phenotypes, Genotypes, Diagnosis, and Treatment Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with these disorders present with a wide range of symptoms, including developmental delay, seizures, movement disorder, behavioral problems, and hypotonia.
    explanation: Confirms hypotonia among the symptom spectrum.
- name: Autism
  frequency: OCCASIONAL
  description: 'Autistic features and autistic-like behavior are reported in a subset of patients with GAMT deficiency.

    '
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Other symptoms include learning disorders, autistic behaviour, epileptic seizures, and movement disorders.
    explanation: Identifies autistic behaviour as a recognized symptom.
- name: Abnormality of the globus pallidus
  frequency: OCCASIONAL
  description: 'MRI shows increased signal in the globus pallidus, and T2 hyperintensities in the basal ganglia have been reported.

    '
  phenotype_term:
    preferred_term: Abnormal globus pallidus morphology
    term:
      id: HP:0002453
      label: Abnormal globus pallidus morphology
  evidence:
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The MRI scan shows an increased signal in the globus pallidus, and the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine.
    explanation: Directly describes globus pallidus signal abnormality on MRI.
- name: Absent speech
  frequency: OCCASIONAL
  description: 'In severe cases, patients may have absent or extremely limited speech production, representing the severe end of the speech/language impairment spectrum.

    '
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Limited speech development in untreated cases can progress to absent speech in severe presentations.
- name: Involuntary movements
  frequency: OCCASIONAL
  description: 'Involuntary movements are described as a feature of untreated GAMT deficiency, distinct from the broader movement disorder category.

    '
  phenotype_term:
    preferred_term: Involuntary movements
    term:
      id: HP:0004305
      label: Involuntary movements
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Untreated, GAMT deficiency is associated with hypotonia, significant intellectual disability, limited speech development, recurrent seizures, behavior problems, and involuntary movements.
    explanation: Explicitly lists involuntary movements among associated features.
biochemical:
- name: Guanidinoacetate
  presence: INCREASED
  context: 'Guanidinoacetate (GAA) is markedly elevated in plasma, urine, CSF, and brain in GAMT deficiency. Elevated GAA is the primary diagnostic biomarker and is considered neurotoxic. It can be detected by tandem mass spectrometry in newborn screening programs.

    '
  biomarker_term:
    preferred_term: guanidinoacetate
    term:
      id: CHEBI:131444
      label: guanidinoacetate
  readouts:
  - target: Deficient creatine biosynthesis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Elevated guanidinoacetate reports the blocked GAMT-dependent conversion
      of guanidinoacetate to creatine.
  - target: Guanidinoacetate neurotoxicity
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >
      Plasma, CSF, urine, or brain guanidinoacetate tracks the toxic upstream
      metabolite burden targeted by substrate-reduction therapy.
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Confirms neurotoxic GAA accumulation as a defining feature.
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine.
    explanation: Confirms elevated urinary GAA as a diagnostic marker.
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet
    explanation: Documents elevated baseline plasma/CSF GAA that decreases with treatment.
- name: Creatine
  presence: DECREASED
  context: 'Creatine is depleted in plasma, urine, CSF, and brain. Cerebral creatine deficiency is detectable by proton magnetic resonance spectroscopy (1H-MRS), which shows absent or markedly decreased creatine peak. Brain creatine may not fully normalize even with long-term treatment.

    '
  biomarker_term:
    preferred_term: creatine
    term:
      id: CHEBI:16919
      label: creatine
  readouts:
  - target: Deficient creatine biosynthesis
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Low creatine reports the missing product of the blocked GAMT-dependent
      creatine biosynthetic step.
  - target: Impaired neuronal energy homeostasis
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: MONITORING
    interpretation: >
      Persistently low brain creatine on spectroscopy tracks the residual
      creatine/phosphocreatine energy-buffer deficit during treatment.
  evidence:
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the diagnosis is confirmed by finding increased guanidinoacetate in the urine and a low plasma creatine.
    explanation: Confirms low plasma creatine as a diagnostic finding.
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges.
    explanation: Shows that even with treatment, brain creatine does not normalize, confirming baseline deficiency.
  - reference: PMID:36856349
    reference_title: "Creatine Deficiency Disorders: Phenotypes, Genotypes, Diagnosis, and Treatment Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diagnosis can be suspected by elevated guanidinoacetate and low creatine levels in body fluids in guanidinoacetate methyltransferase deficiency
    explanation: Confirms low creatine in body fluids as a diagnostic marker.
- name: Creatine on brain MRS
  presence: DECREASED
  context: 'Proton magnetic resonance spectroscopy (1H-MRS) of the brain shows absent or markedly decreased creatine peak, which serves as a non-invasive diagnostic and monitoring tool for cerebral creatine deficiency.

    '
  biomarker_term:
    preferred_term: creatine
    term:
      id: CHEBI:16919
      label: creatine
  readouts:
  - target: Impaired neuronal energy homeostasis
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: MONITORING
    interpretation: >
      Brain MRS creatine is a tissue-level readout of cerebral creatine
      repletion and remaining neuronal energy-buffer deficiency.
  evidence:
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the creatine concentrations, which were regularly monitored over a long follow-up period, increased significantly over time, but did not reach age matched control ranges.
    explanation: Confirms decreased brain creatine on MRS that improves but does not normalize with treatment.
- name: Creatinine
  presence: DECREASED
  notes: 'Low creatinine in urine may also be observed since creatinine is derived from creatine. Urine creatine-to-creatinine ratio may be informative for differential diagnosis within cerebral creatine deficiency syndromes.

    '
  context: 'Low urinary creatinine reflects the underlying creatine depletion state. Creatine-to-creatinine ratio in urine helps distinguish GAMT deficiency from creatine transporter deficiency.

    '
genetic:
- name: GAMT pathogenic variants
  gene_term:
    preferred_term: GAMT
    term:
      id: hgnc:4136
      label: GAMT
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:37465909
      reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene
      explanation: Explicitly states autosomal recessive inheritance.
    - reference: PMID:19289269
      reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The condition is inherited in an autosomal recessive manner, and mutations in the GAMT gene severely affect the activity of guanidinoacetate.
      explanation: Confirms autosomal recessive inheritance pattern.
  features: 'GAMT deficiency is caused by biallelic pathogenic variants in GAMT (chromosome 19p13.3), encoding guanidinoacetate N-methyltransferase. The enzyme catalyzes methylation of guanidinoacetate to creatine using S-adenosylmethionine as the methyl donor. Loss-of-function variants result in deficient enzymatic activity, leading to creatine depletion and GAA accumulation. Consanguinity is a risk factor; 23% of affected cases in one scoping review were from consanguineous marriages. Countries with high consanguinity rates such as Saudi Arabia may have higher prevalence.

    '
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene that lead to cerebral creatine deficiency and neurotoxic levels of guanidinoacetate.
    explanation: Confirms pathogenic variants in GAMT as the cause.
  - reference: PMID:39006040
    reference_title: "Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency: An Analytical Study of a Case Series and a Scoping Review of 53 Cases of Guanidinoacetate N-Methyltransferase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 23% of the affected cases were of consanguineous marriages, and 7% had affected relatives.
    explanation: Quantifies consanguinity as a risk factor in the scoping review.
  - reference: PMID:39006040
    reference_title: "Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency: An Analytical Study of a Case Series and a Scoping Review of 53 Cases of Guanidinoacetate N-Methyltransferase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase deficiency (GAMT) is an autosomal recessive inborn error of metabolism. A condition that results from a pathogenic variant in the GAMT gene that maps to 19p13.3.
    explanation: Confirms the chromosomal location and autosomal recessive nature.
  - reference: CGGV:assertion_f0a84d45-57f8-4763-b1c5-7a283cef5f71-2019-01-25T170000.000Z
    reference_title: "GAMT / guanidinoacetate methyltransferase deficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GAMT | HGNC:4136 | guanidinoacetate methyltransferase deficiency | MONDO:0012999 | AR | Definitive"
    explanation: ClinGen classifies the GAMT-guanidinoacetate methyltransferase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Creatine supplementation
  description: 'Oral creatine monohydrate is the cornerstone of therapy, aimed at repleting systemic and cerebral creatine stores. Typical dosing is approximately 400-800 mg/kg/day. Treatment is associated with improvement of cerebral creatine on MRS and clinical symptom stabilization or improvement, though brain creatine may not fully normalize.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: creatine
      term:
        id: CHEBI:16919
        label: creatine
  target_mechanisms:
  - target: Deficient creatine biosynthesis
    treatment_effect: BYPASSES
    description: Oral creatine supplies the downstream product of the blocked GAMT reaction and raises cerebral creatine.
  - target: Impaired neuronal energy homeostasis
    treatment_effect: MODULATES
    description: Repleting cerebral creatine supports the creatine/phosphocreatine energy buffer in brain, though brain creatine may remain below control ranges.
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet
    explanation: Directly supports creatine supplementation as effective in increasing cerebral creatine.
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Therapy was associated with improvement or stabilization of symptoms in all of the symptomatic cases. The 4 patients treated younger than 9 months had normal or almost normal developmental outcomes.
    explanation: Demonstrates clinical benefit of early creatine-based therapy.
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels.
    explanation: Confirms creatine supplementation as a treatment component.
- name: Ornithine supplementation
  description: 'Oral L-ornithine is used as a substrate-reduction strategy to inhibit AGAT activity, thereby reducing guanidinoacetate synthesis. Dosing ranges from 100 to 800 mg/kg/day. Ornithine combined with creatine is more effective than creatine alone at reducing GAA levels.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ornithine
      term:
        id: CHEBI:18257
        label: ornithine
  target_mechanisms:
  - target: Guanidinoacetate neurotoxicity
    treatment_effect: INHIBITS
    description: Ornithine supplementation is used as substrate-reduction therapy to lower toxic GAA levels.
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate and protein/arginine restricted diets.
    explanation: Confirms ornithine as a standard treatment component.
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet
    explanation: Demonstrates that high-dose ornithine contributes to GAA reduction.
  - reference: PMID:38469086
    reference_title: "Long term follow-up in GAMT deficiency - Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists of daily creatine supplementation to increase cerebral creatine, reduction of arginine intake and supplementation of ornithine for reduction of toxic GAA levels.
    explanation: Confirms ornithine's role in reducing toxic GAA levels.
- name: Protein/arginine-restricted diet
  description: 'Dietary restriction of protein and/or arginine intake reduces the precursor supply for guanidinoacetate synthesis via AGAT, serving as a substrate-reduction approach. This is typically combined with creatine and ornithine supplementation.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Guanidinoacetate neurotoxicity
    treatment_effect: INHIBITS
    description: Restricting protein and arginine reduces precursor flux into guanidinoacetate synthesis.
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increase of cerebral creatine and decrease of plasma/CSF guanidinoacetate levels were achieved by supplementation with creatine-monohydrate combined with high dosages of l-ornithine and/or an arginine-restricted diet (250 mg/kg/d l-arginine).
    explanation: Supports arginine-restricted diet as part of the effective treatment regimen.
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment is based on giving creatine supplementation orally and a low-protein diet with restricted arginine and increased ornithine.
    explanation: Confirms low-protein, arginine-restricted diet as a standard treatment.
- name: Sodium benzoate therapy
  description: 'Sodium benzoate is used in some treatment protocols to reduce glycine availability, a precursor for guanidinoacetate synthesis. Dosing is approximately 100 mg/kg/day. This reduces the substrate pool available for AGAT, contributing to GAA lowering.

    '
  treatment_term:
    preferred_term: nitrogen scavenger therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sodium benzoate
      term:
        id: CHEBI:113455
        label: sodium benzoate
  target_mechanisms:
  - target: Guanidinoacetate neurotoxicity
    treatment_effect: INHIBITS
    description: Sodium benzoate reduces glycine availability, limiting substrate input into guanidinoacetate production.
  evidence:
  - reference: PMID:24268530
    reference_title: "Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment regimens included various combinations/dosages of creatine-monohydrate, l-ornithine, sodium benzoate and protein/arginine restricted diets.
    explanation: Confirms sodium benzoate as a component of treatment protocols.
- name: Newborn screening
  description: 'GAMT deficiency screening can be incorporated into existing tandem mass spectrometry newborn screening platforms, detecting elevated guanidinoacetate. The Advisory Committee on Heritable Disorders in Newborns and Children recommended addition to the RUSP, accepted in January 2023. Presymptomatic detection enables early treatment initiation before irreversible neurologic damage.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  target_phenotypes:
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the feasibility of screening, the low number of positive results, the relative ease of diagnosis, and the expected benefit of presymptomatic dietary therapy led to a recommendation from the Advisory Committee on Heritable Disorders in Newborns and Children to the Secretary of Health and Human Services that GAMT deficiency be added to the Recommended Uniform Screening Panel. This recommendation was accepted in January 2023.
    explanation: Documents the policy decision to add GAMT deficiency to the RUSP.
- name: Anticonvulsant therapy
  description: 'Antiepileptic medications are used to manage seizures, which affect approximately 70% of patients. Seizure improvement is often observed with metabolic treatment (creatine supplementation), sometimes allowing reduction of anticonvulsant medications.

    '
  treatment_term:
    preferred_term: antiepileptic drug therapy
    term:
      id: MAXO:0000167
      label: anticonvulsant agent therapy
    therapeutic_agent:
    - preferred_term: anticonvulsant agent
      term:
        id: NCIT:C264
        label: Anticonvulsant Agent
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:19289269
    reference_title: "Guanidinoacetate methyltransferase deficiency (GAMT)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This results in improvement of many of the symptoms, especially of the epileptic seizures and the abnormal movements.
    explanation: Notes that treatment improves epileptic seizures, implying anticonvulsant management is part of care.
- name: Genetic counseling
  description: 'Genetic counseling for affected families covers autosomal recessive inheritance, 25% recurrence risk, carrier testing, prenatal diagnosis, and the importance of premarital genetic testing in populations with high consanguinity rates.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:39006040
    reference_title: "Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency: An Analytical Study of a Case Series and a Scoping Review of 53 Cases of Guanidinoacetate N-Methyltransferase."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Premarital testing of neurogenetic diseases using whole-exome sequencing is probably a future direction, especially in populations with high consanguinity rates.
    explanation: Supports genetic counseling and carrier testing, particularly in consanguineous populations.
  - reference: PMID:37465909
    reference_title: "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessive disorder of creatine biosynthesis due to pathogenic variants in the GAMT gene
    explanation: Autosomal recessive inheritance necessitates genetic counseling for family planning.
- name: Gene therapy (investigational)
  description: 'AAV-based gene therapy expressing human GAMT in hepatocytes is under preclinical development. In a murine model, liver-directed gene therapy achieved pan-hepatic GAMT expression, marked and sustained reduction of GAA, normalization of plasma creatine, increased cerebral and myocardial creatine, and resolution of behavioral abnormalities. CNS-directed AAV9 approaches are also being investigated.

    '
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: GAMT molecular function deficiency
    treatment_effect: RESTORES
    description: AAV-mediated GAMT delivery is designed to restore hepatocyte GAMT expression in preclinical models.
  - target: Deficient creatine biosynthesis
    treatment_effect: RESTORES
    description: Restoring GAMT expression normalizes plasma creatine and reduces GAA in the mouse model.
  notes: 'Gene therapy for GAMT deficiency remains investigational and is not yet available clinically. Both liver-directed and CNS-directed AAV vector approaches are being explored in preclinical models.

    '
  evidence:
  - reference: PMID:35505663
    reference_title: "Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Serial collection of blood demonstrated a marked early and sustained reduction of GAA with normalization of plasma creatine; urinary GAA levels also markedly declined.
    explanation: Shows sustained biochemical correction in the gene therapy mouse model.
  - reference: PMID:35505663
    reference_title: "Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The terminal time point demonstrated marked improvement in cerebral and myocardial creatine levels. In conjunction with the biochemical findings, treated mice gained weight to nearly match their wild-type littermates, while behavioral studies demonstrated resolution of abnormalities
    explanation: Demonstrates improved cerebral/myocardial creatine and resolved behavioral phenotype with gene therapy.
notes: 'GAMT deficiency is one of three cerebral creatine deficiency syndromes (CCDS), alongside AGAT deficiency (GATM mutations) and creatine transporter deficiency (SLC6A8 mutations). GAMT deficiency is distinguished by elevated guanidinoacetate (rather than low GAA in AGAT deficiency or elevated urine creatine-to-creatinine ratio in SLC6A8 deficiency). Treatment is most effective when initiated presymptomatically, as demonstrated by normal/near-normal outcomes in the four patients treated before 9 months in the landmark 48-patient cohort. This underscores the importance of newborn screening, which was added to the US RUSP in January 2023. Long-term monitoring with 1H-MRS shows that brain creatine may increase with treatment but typically does not reach age-matched control ranges, motivating ongoing development of curative gene therapy approaches. Failure to thrive and feeding difficulties are reported clinically in some patients but are not retained as an evidence-backed phenotype assertion in this entry.

  '
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 23 citations 2026-02-23T23:44:36.845922

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Guanidinoacetate Methyltransferase Deficiency
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Guanidinoacetate Methyltransferase Deficiency. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Pathophysiology Research Report: Guanidinoacetate Methyltransferase (GAMT) Deficiency

Target disease and identifiers

Disease name and category: Guanidinoacetate methyltransferase (GAMT) deficiency; genetic, autosomal recessive disorder of creatine biosynthesis. (ream2023evidenceandrecommendation pages 1-3) Common alternate naming used in the literature: Cerebral creatine deficiency syndrome (CCDS) due to a creatine-synthesis defect. (alyazidi2024phenotypicandmolecular pages 1-2, binsfeld2026acnsdirectedaav9 pages 1-3) Key identifiers available in retrieved sources: - OMIM (disease): OMIM #612736 (as reported in a 2023 review table of creatine deficiency disorders). (mulik2023creatinedeficiencydisorders pages 2-3) - OMIM (gene): GAMT gene is cited as MIM #601240 in a 2023 Pediatrics newborn screening evidence review. (ream2023evidenceandrecommendation pages 1-3) MONDO ID: Not found in the retrieved full-text excerpts; therefore not reported here.

Executive summary (current understanding)

GAMT deficiency is caused by biallelic loss-of-function variants in GAMT (19p13.3), which encodes guanidinoacetate methyltransferase, the enzyme that catalyzes the final step of endogenous creatine biosynthesis by methylating guanidinoacetate (GAA) to creatine using S-adenosylmethionine as methyl donor. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) The canonical biochemical signature is systemic and cerebral creatine depletion together with accumulation of guanidinoacetate in biofluids and brain. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) Disease mechanisms are increasingly framed as the combined effect of (i) creatine deficiency (impaired ATP buffering/energy shuttle) and (ii) GAA neurotoxicity, including evidence implicating altered GABAergic neurotransmission and seizure susceptibility. (marten2024longtermfollowup pages 1-2, khoja2022genetherapyfor pages 1-2) Clinically, the disorder is a neurodevelopmental encephalopathy with prominent developmental delay/intellectual disability, severe speech impairment, epilepsy, behavioral disturbances, and movement disorders; early/presymptomatic treatment is associated with substantially better neurodevelopmental outcomes, motivating newborn screening implementation. (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, ream2023evidenceandrecommendation pages 3-4)

  1. Key concepts and definitions (core pathophysiology)

1.1 Creatine metabolism and “cerebral creatine deficiency” Creatine is a key metabolite for energy homeostasis via the creatine/phosphocreatine system that buffers and rapidly regenerates ATP during fluctuating demand. A 2023 evidence review describes creatine as “a critical energy source for cellular metabolism” and links GAMT deficiency to cerebral creatine depletion. (ream2023evidenceandrecommendation pages 1-3) In GAMT deficiency, creatine is low in plasma and brain, while guanidinoacetate is elevated in brain, CSF, blood, and urine. (ream2023evidenceandrecommendation pages 1-3) A frequently used clinical imaging definition of cerebral creatine deficiency is the reduction/absence of the creatine peak on proton magnetic resonance spectroscopy (1H-MRS); a 2023 review summarizes that GAMT deficiency shows “absent or markedly decreased Cr in brain 1H-MRS.” (mulik2023creatinedeficiencydisorders pages 2-3)

1.2 Enzymatic defect and pathway position Creatine is biosynthesized from arginine and glycine through two key steps: (i) AGAT produces guanidinoacetate (GAA), and (ii) GAMT methylates GAA to creatine. Loss of GAMT blocks this final step, causing creatine deficiency and GAA accumulation. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2) A 2024 long-term follow-up report reiterates that GAMT uses S-adenosylmethionine (SAM) as the methyl donor in this conversion and that the consequence is “cerebral creatine depletion and accumulation of guanidinoacetate.” (marten2024longtermfollowup pages 1-2)

1.3 Dual-mechanism disease model: creatine deficiency plus GAA toxicity The 2023 Pediatrics review explicitly frames pathophysiology as low creatine plus “neurotoxic levels of guanidinoacetate.” (ream2023evidenceandrecommendation pages 1-3) Mechanistically, creatine deficiency is expected to impair neuronal energy buffering (creatine/phosphocreatine shuttle), whereas elevated GAA can exert direct neurotoxicity and pro-convulsant effects. (marten2024longtermfollowup pages 1-2, khoja2022genetherapyfor pages 1-2)

  1. Dysregulated molecular pathways and affected cellular processes

2.1 Dysregulated metabolic pathways - Creatine biosynthetic process / creatine metabolic process: loss of GAMT blocks endogenous creatine production, leading to low creatine in body fluids and brain. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) - Guanidinoacetate (GAA) handling: precursor overproduction and/or impaired clearance leads to systemic and CNS accumulation. (ream2023evidenceandrecommendation pages 1-3) - One-carbon/methylation burden (conceptual mechanism): because GAMT consumes methyl groups from SAM, perturbations and/or therapeutic manipulation of guanidinoacetate can affect methyl balance; a 2023 review cautions about risks including “methyl group depletion” and “guanidinoacetate-driven hyperhomocysteinemia.” (mulik2023creatinedeficiencydisorders pages 2-3)

2.2 Cellular processes affected - Bioenergetic buffering / ATP homeostasis: creatine is required for rapid ATP regeneration via phosphocreatine; creatine deficiency is linked to impaired energy metabolism and neurodevelopmental dysfunction. (ream2023evidenceandrecommendation pages 1-3, khoja2022genetherapyfor pages 1-2) - Neurotransmission and excitability (GABAergic mechanisms): a 2024 follow-up paper cites mechanistic work indicating that “Guanidinoacetate (GAA) is a potent GABAA receptor GABA mimetic,” supporting a plausible direct mechanism for seizures and altered inhibitory neurotransmission in GAMT deficiency. (marten2024longtermfollowup pages 7-7) - Neurodevelopmental processes: a preclinical gene-therapy report notes creatine’s roles beyond energy buffering, including neurite growth and neurotransmission, consistent with developmental vulnerability of the CNS in GAMT deficiency. (khoja2022genetherapyfor pages 1-2)

  1. Key molecular players (genes/proteins, metabolites, cell types, tissues)

3.1 Genes and proteins (HGNC-style gene symbols) Primary causal gene - GAMT (guanidinoacetate methyltransferase): biallelic pathogenic variants cause disease; autosomal recessive inheritance. (ream2023evidenceandrecommendation pages 1-3) Pathway and related genes (frequently co-discussed in CCDS literature) - GATM (AGAT): upstream enzyme producing guanidinoacetate; relevant for understanding substrate-reduction therapies and differential diagnosis. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2) - SLC6A8 (creatine transporter): not causal for GAMT deficiency, but central to creatine uptake and to broader “cerebral creatine deficiency syndromes” context; important for interpreting why oral creatine may incompletely restore CNS creatine. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2) Variant interpretation / authoritative genomic curation - ClinGen curation efforts for CCDS genes (including GAMT) have produced 2024 recommendations for variant classification, supporting consistent interpretation of pathogenicity. (binsfeld2026acnsdirectedaav9 pages 1-3)

3.2 Chemical entities (CHEBI-style) Core metabolites - Creatine (Cr): deficient in plasma/CSF/brain and urine in GAMT deficiency; therapeutic replacement is a cornerstone. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) - Guanidinoacetate / guanidinoacetic acid (GAA): accumulates systemically and in the CNS and is considered neurotoxic. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) - S-adenosylmethionine (SAM): methyl donor required by GAMT; relevant to methylation balance considerations. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) Therapeutic small molecules/dietary agents used in practice - Creatine monohydrate: typical dosing in reviews ~400–800 mg/kg/day. (mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 3-4) - L-ornithine: used to reduce GAA synthesis by inhibiting AGAT (substrate reduction); dosing ranges described (e.g., 100–800 mg/kg/day). (ream2023evidenceandrecommendation pages 3-4) - Sodium benzoate: used in some regimens to reduce glycine availability (and thereby GAA synthesis); included in presymptomatic protocols. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4) - Protein/arginine-restricted diet: reduces precursor supply for GAA. (ream2023evidenceandrecommendation pages 1-3, mulik2023creatinedeficiencydisorders pages 2-3)

3.3 Cell types (CL-style) and tissues/anatomical locations (UBERON-style) CNS involvement is primary - Brain (UBERON: brain): cerebral creatine deficiency is detectable by 1H-MRS; clinical sequelae are neurological. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) - Basal ganglia (UBERON: basal ganglion): reported MRI T2 hyperintensities in some cases. (marten2024longtermfollowup pages 1-2) Peripheral tissues relevant for metabolism and emerging therapies - Liver (UBERON: liver): frequently emphasized as a key site for creatine biosynthesis and a target for gene therapy approaches; a 2022 AAV strategy achieved pan-hepatic expression with systemic biochemical correction. (khoja2022genetherapyfor pages 1-2) - Heart/myocardium (UBERON: myocardium): gene therapy in a mouse model increased myocardial creatine. (khoja2022genetherapyfor pages 1-2) Cell-type specificity (current model) The literature increasingly emphasizes compartmentation of creatine synthesis/transport across tissues and (in the CNS) across cell types, supporting why deficiency manifests strongly in brain and why restoring brain creatine is challenging. (khoja2022genetherapyfor pages 1-2, binsfeld2026acnsdirectedaav9 pages 1-3)

  1. Biological processes and cellular components (for ontology annotation)

4.1 Candidate disrupted GO biological processes (mechanistically grounded) - Creatine biosynthetic process / creatine metabolic process (blocked GAMT-mediated methylation step). (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) - Guanidinoacetate metabolic process (pathologic accumulation). (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) - Cellular energy homeostasis / ATP metabolic process (creatine described as critical for cellular energy metabolism). (ream2023evidenceandrecommendation pages 1-3, khoja2022genetherapyfor pages 1-2) - GABAergic synaptic transmission / regulation of membrane potential / seizure susceptibility (supported by evidence that GAA can act as a GABAA receptor mimetic). (marten2024longtermfollowup pages 7-7) - Neurodevelopmental processes (neurite outgrowth and neurotransmission roles of creatine, consistent with developmental phenotypes). (khoja2022genetherapyfor pages 1-2)

4.2 Candidate GO cellular components - Cytosol (site of creatine/phosphocreatine buffering reactions broadly discussed in creatine biology). (khoja2022genetherapyfor pages 1-2) - Mitochondrial-associated energy-transfer interface (conceptual location for creatine kinase energy shuttle; described as an energy shuttle between ATP production and utilization sites). (khoja2022genetherapyfor pages 1-2) - Synapse / postsynaptic membrane (implicated by GABAA receptor mechanism for GAA). (marten2024longtermfollowup pages 7-7)

  1. Disease progression: sequence of events from trigger to clinical manifestations

5.1 Initiation - Genetic trigger: biallelic pathogenic variants in GAMT lead to deficient GAMT enzymatic activity. (ream2023evidenceandrecommendation pages 1-3, mulik2023creatinedeficiencydisorders pages 1-2) - Early life masking: newborns may be asymptomatic at birth, attributed to in utero/placental creatine transfer, with symptoms developing later without treatment. (ream2023evidenceandrecommendation pages 1-3)

5.2 Early biochemical derangements - Reduced conversion of GAA to creatine leads to systemic and cerebral creatine depletion and GAA accumulation in biofluids and brain/CSF. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2)

5.3 Cellular dysfunction and network-level consequences - Energetic stress: reduced creatine/phosphocreatine buffering capacity in high-energy tissues (notably brain) contributes to neurodevelopmental dysfunction. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) - Neurotoxicity/excitability: elevated GAA is considered neurotoxic and may perturb inhibitory neurotransmission, with mechanistic support via GABAA receptor mimicry. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 7-7)

5.4 Clinical manifestation and long-term course - Progressive neurodevelopmental phenotype: hypotonia, developmental delay/intellectual disability, severe speech impairment, epilepsy, behavioral problems, and movement disorder. (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2) - Critical window: The evidence base emphasizes that once significant impairment develops, treatment benefit may be limited; presymptomatic treatment is associated with markedly better outcomes. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4)

  1. Phenotypic manifestations and mechanism links (HP-style terms)

Key phenotypes (with approximate frequencies from cohorts/reviews) - Global developmental delay / intellectual disability (HP: Global developmental delay; HP: Intellectual disability): 44/48 (~92%) in a 48-person cohort; 100% in a 2023 review table summary. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3) - Severe speech/language impairment (HP: Delayed speech and language development): highlighted as prominent feature. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, ream2023evidenceandrecommendation pages 1-3) - Seizures/epilepsy (HP: Seizure; HP: Epilepsy): 35/48 (~73%) in cohort; ~70% in 2023 review table; often recurrent seizures clinically. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Behavioral abnormalities (HP: Behavioral abnormality; autism-like features): ~75% in 2023 review table; described as “severe behavioral disorders” in evidence review. (mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Movement disorder (HP: Dystonia; HP: Ataxia; HP: Movement abnormality): 13/48 (~27%) in cohort; ~30% in review table; includes dystonia/ataxia. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Hypotonia (HP: Hypotonia): common clinical feature noted in evidence review. (ream2023evidenceandrecommendation pages 1-3)

Mechanistic links (examples) - Seizures plausibly reflect both energetic instability and direct GAA effects on inhibitory neurotransmission; mechanistic support is the cited finding that GAA is a “potent GABAA receptor GABA mimetic.” (marten2024longtermfollowup pages 7-7) - Developmental delay and speech impairment align with creatine’s role in cellular energy metabolism and neurodevelopmental processes. (ream2023evidenceandrecommendation pages 1-3, khoja2022genetherapyfor pages 1-2)

  1. Recent developments and latest research (prioritizing 2023–2024)

7.1 Newborn screening policy and implementation (2023) A major translational development is the US recommendation to add GAMT deficiency to newborn screening: the Advisory Committee on Heritable Disorders in Newborns and Children recommended addition to the Recommended Uniform Screening Panel (RUSP), and “This recommendation was accepted in January 2023.” (ream2023evidenceandrecommendation pages 1-3) The Pediatrics evidence review summarizes why screening is impactful: without screening, diagnosis often occurs after significant neurologic injury, whereas presymptomatic dietary/supplement therapy “appear to substantially improve health and developmental outcomes.” (ream2023evidenceandrecommendation pages 1-3)

7.2 Standardization of variant interpretation (2024) ClinGen expert panel recommendations (2024) for classification of variants in GAMT (and related CCDS genes) aim to harmonize molecular diagnosis and clinical interpretation, which is increasingly important with newborn screening expansion and increased genomic testing. (binsfeld2026acnsdirectedaav9 pages 1-3)

7.3 Long-term clinical monitoring with MR spectroscopy and biochemical correlation (2024) A 2024 long-term follow-up report illustrates long-horizon monitoring using plasma/urine metabolites and in vivo brain 1H-MRS (including incorporation of a GAA signal into MRS quantification), tying therapy regimen to biochemical and brain spectroscopy outcomes over many years. (marten2024longtermfollowup pages 1-2, marten2024longtermfollowup pages 2-4)

7.4 Updated phenotype spectrum synthesis (2024) A 2024 scoping review of 53 cases reported that ~79% developed symptoms before age 5 and found seizures in ~68% and developmental delay in ~84%, reinforcing the typical early-onset neurodevelopmental presentation. (alyazidi2024phenotypicandmolecular pages 1-2)

  1. Current applications and real-world implementations

8.1 Diagnostic workflow in real practice Core biochemical diagnosis uses elevated guanidinoacetate and low creatine in body fluids (plasma/urine/CSF) and low brain creatine on 1H-MRS, followed by genetic confirmation. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) Newborn screening integration: GAMT deficiency screening can be added to existing tandem mass spectrometry newborn screening, with about 1 per 100,000 newborns screening positive, and diagnosis then confirmed with elevated guanidinoacetate and low creatine in blood. (ream2023evidenceandrecommendation pages 1-3)

8.2 Therapeutic approach in clinical care (mechanism-based) - Creatine supplementation aims to replete systemic and brain creatine. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) - Ornithine supplementation and arginine/protein restriction aim to reduce precursor availability and suppress GAA synthesis (substrate reduction). (mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Sodium benzoate is used in some protocols to reduce glycine availability (a precursor), contributing to lowering GAA. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4)

8.3 Emerging and preclinical “root-cause” approaches A 2022 preclinical study reports AAV-based gene therapy expressing human GAMT with pan-hepatic expression, producing “early and sustained” reduction in GAA, normalization of plasma creatine, and increased cerebral and myocardial creatine, alongside improved behavioral and weight phenotypes in a murine model. (khoja2022genetherapyfor pages 1-2)

  1. Expert opinions / authoritative analysis

The Pediatrics evidence review (American Academy of Pediatrics journal) provides a policy-oriented synthesis concluding that feasibility of tandem-MS screening, low screen-positive rate, and expected benefit of presymptomatic therapy justify inclusion on the RUSP, emphasizing that diagnosis is otherwise delayed and treatment later has limited ability to reverse established impairment. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 4-6) Long-term follow-up literature emphasizes that therapy improves biochemical abnormalities but may not fully normalize metabolites in all compartments (especially brain), reinforcing the need for early initiation and sustained management and motivating curative strategies. (marten2024longtermfollowup pages 1-2, khoja2022genetherapyfor pages 1-2)

  1. Statistics and data from recent studies (selected)

10.1 Prevalence/incidence and screening yields - Birth prevalence estimate (reviewed): likely between 0.5 and 2 per million live births. (ream2023evidenceandrecommendation pages 1-3) - Screening positive rate: “about 1 per 100,000 newborns” screen positive in newborn screening settings. (ream2023evidenceandrecommendation pages 1-3) - Programmatic case detection examples summarized in 2023: - Australia: 1 case in 1.4 million screened. - Utah: 321,305 screened, 3 referrals, 1 case. - New York: 759,246 screened, 24 referrals, 1 case. (As summarized in the Pediatrics evidence review.) (ream2023evidenceandrecommendation pages 3-4)

10.2 Diagnostic delay (real-world natural history) The Pediatrics evidence review summarizes that symptoms were first noticed at mean ~14 months (range 3–24 months) but mean age at diagnosis was ~8.5 years (range 9 months–25 years) in the published literature it reviewed. (ream2023evidenceandrecommendation pages 3-4)

10.3 Phenotype frequencies - 48-person cohort: developmental delay/intellectual disability 44/48 (~92%); epilepsy 35/48 (~73%); movement disorder 13/48 (~27%). (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2) - 2023 review table: seizures ~70%; behavioral disorders ~75%; movement disorders ~30%; developmental delay/cognitive dysfunction/intellectual disability 100%. (mulik2023creatinedeficiencydisorders pages 2-3) - 2024 scoping review: seizures ~68%; developmental delay ~84%; intellectual disability/mental retardation ~43%; ~79% onset before age 5. (alyazidi2024phenotypicandmolecular pages 1-2)

10.4 Treatment dosing and monitoring examples - Reported dosing ranges used in presymptomatic/early regimens include creatine ~400 mg/kg/day and ornithine 100–800 mg/kg/day, with optional sodium benzoate ~100 mg/kg/day and dietary measures. (ream2023evidenceandrecommendation pages 3-4) - A 2024 long-term follow-up case report describes starting creatine 400 mg/kg/day and ornithine 100 mg/kg/day at 15 months and observing clinical improvement after 3 months; it also reports laboratory reference ranges (e.g., urine GAA reference range for age 0–<6 months noted as 4–220 µM/mM creatinine; creatine/creatinine ratio 0.006–1.2 for that age band). (marten2024longtermfollowup pages 2-4)

Knowledge-base oriented annotations (structured summary)

A. Pathophysiology description (knowledge-base narrative) GAMT deficiency is an autosomal recessive inborn error of creatine biosynthesis caused by biallelic pathogenic variants in GAMT, which catalyzes methylation of guanidinoacetate to creatine using SAM. Loss of GAMT produces systemic and cerebral creatine depletion with concomitant guanidinoacetate accumulation in biofluids and brain/CSF, resulting in a combined mechanism of impaired cellular energy buffering (creatine/phosphocreatine shuttle dysfunction) and guanidinoacetate neurotoxicity. Clinical manifestations are dominated by early-onset neurodevelopmental impairment with prominent speech delay, epilepsy, behavioral abnormalities, hypotonia, and movement disorder, with strong evidence that presymptomatic treatment substantially improves outcomes and motivates newborn screening implementation. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2, marten2024longtermfollowup pages 7-7)

B. Gene/protein annotations (examples) - GAMT (HGNC symbol: GAMT): molecular function—methyltransferase activity; biological process—creatine biosynthesis; disease mechanism—loss-of-function causes low creatine + high GAA. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) Related pathway genes for context and differential diagnosis - GATM (AGAT): guanidinoacetate biosynthesis step; pharmacologic/dietary substrate reduction targets this step indirectly. (mulik2023creatinedeficiencydisorders pages 1-2) - SLC6A8: creatine transport into cells/brain; affects effectiveness of creatine repletion strategies in CCDS broadly. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2)

C. Phenotype associations (HP-style; non-exhaustive) - HP: Global developmental delay; HP: Intellectual disability (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3) - HP: Seizure / HP: Epilepsy (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3) - HP: Abnormality of movement / HP: Dystonia / HP: Ataxia (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2) - HP: Behavioral abnormality (ream2023evidenceandrecommendation pages 1-3, mulik2023creatinedeficiencydisorders pages 2-3) - HP: Hypotonia (ream2023evidenceandrecommendation pages 1-3)

D. Cell type involvement (CL-style; mechanistic emphasis) - CL: neuron; CL: astrocyte; CL: brain microvascular endothelial cell (as a conceptual schema for compartmentalized creatine synthesis/transport underlying CNS vulnerability and incomplete CNS repletion). (binsfeld2026acnsdirectedaav9 pages 1-3, khoja2022genetherapyfor pages 1-2)

E. Anatomical locations (UBERON-style) - UBERON: brain; UBERON: basal ganglion (marten2024longtermfollowup pages 1-2) - UBERON: liver; UBERON: heart/myocardium (khoja2022genetherapyfor pages 1-2)

F. Chemical entities (CHEBI-style) - CHEBI: creatine; CHEBI: guanidinoacetate/guanidinoacetic acid; CHEBI: S-adenosylmethionine; CHEBI: ornithine; CHEBI: sodium benzoate. (mulik2023creatinedeficiencydisorders pages 1-2, ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4)

Evidence items (with publication date and URL; PMIDs)

Note on PMIDs: The retrieved full-text excerpts frequently contain DOI and URL metadata but did not consistently include PMIDs. Where PMIDs are required, consult PubMed using DOI-to-PMID mapping for each citation below.

1) Newborn screening evidence and epidemiology - Ream MA et al. “Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening.” Pediatrics. Published July 2023. https://doi.org/10.1542/peds.2023-062100 (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4, ream2023evidenceandrecommendation pages 4-6)

2) 2024 long-term follow-up, MRS/biochemical correlation - Marten LM et al. “Long term follow-up in GAMT deficiency – Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data.” Molecular Genetics and Metabolism Reports. Published March 2024. https://doi.org/10.1016/j.ymgmr.2024.101053 (marten2024longtermfollowup pages 1-2, marten2024longtermfollowup pages 2-4)

3) 2023 clinical review (phenotypes, biomarkers, treatment dosing) - Mulik C, Mercimek-Andrews S. “Creatine Deficiency Disorders: Phenotypes, Genotypes, Diagnosis, and Treatment Outcomes.” Turkish Archives of Pediatrics. Published March 2023. https://doi.org/10.5152/turkarchpediatr.2023.23022 (mulik2023creatinedeficiencydisorders pages 2-3)

4) Cohort outcomes and diagnosis/treatment recommendations (landmark) - Stöckler-Ipsiroglu S et al. “Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring.” Molecular Genetics and Metabolism. Published January 2014. https://doi.org/10.1016/j.ymgme.2013.10.018 (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2)

5) 2024 phenotype spectrum synthesis (scoping review) - Alyazidi AS et al. “Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency … Scoping Review of 53 Cases …” Journal of Microscopy and Ultrastructure. Published December 2024. https://doi.org/10.4103/jmau.jmau_16_22 (alyazidi2024phenotypicandmolecular pages 1-2)

6) Emerging preclinical therapy - Khoja S et al. “Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities.” Molecular Therapy – Methods & Clinical Development. Published June 2022. https://doi.org/10.1016/j.omtm.2022.03.015 (khoja2022genetherapyfor pages 1-2)

Visual evidence retrieved - Table image (Pediatrics 2023) supporting improved outcomes with early-treated vs later-treated siblings (cropped artifact from the paper): (ream2023evidenceandrecommendation media 0689e046)

Limitations of this report (due to retrievable evidence constraints)

  • MONDO and Orphanet identifiers were not present in the retrieved full-text excerpts and thus are not reported.
  • PMIDs were not consistently available in the extracted text chunks; DOIs and URLs are provided for PubMed cross-mapping.
  • Some requested quantitative endpoints (e.g., standardized neurodevelopmental test score effect sizes across cohorts) were not present in the accessible excerpts; however, multiple sources provide outcome directionality and early-treatment benefit trends. (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, ream2023evidenceandrecommendation pages 3-4)

References

  1. (ream2023evidenceandrecommendation pages 1-3): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.

  2. (alyazidi2024phenotypicandmolecular pages 1-2): Anas S. Alyazidi, Osama Y. Muthaffar, Mohammed K. Shawli, Renad A. Ahmed, Yara Fahad Aljefri, Layan Saleh Baaishrah, Abdulaziz T. Jambi, and Fahad A. Alotibi. Phenotypic and molecular spectrum of guanidinoacetate n-methyltransferase deficiency: an analytical study of a case series and a scoping review of 53 cases of guanidinoacetate n-methyltransferase. Journal of Microscopy and Ultrastructure, 12(2):81-90, Dec 2024. URL: https://doi.org/10.4103/jmau.jmau_16_22, doi:10.4103/jmau.jmau_16_22. This article has 2 citations.

  3. (binsfeld2026acnsdirectedaav9 pages 1-3): Robyn Binsfeld, Troy Webster, Ilona Tkachyova, Michael Tropak, Melissa Mitchell, Tesla Peretti, Andreas Schulze, and Jagdeep S. Walia. A cns-directed, aav9 gene therapy restores expression and biochemical function of guanidinoacetate methyltransferase in models of gamt deficiency. International Journal of Molecular Sciences, 27:1035, Jan 2026. URL: https://doi.org/10.3390/ijms27021035, doi:10.3390/ijms27021035. This article has 0 citations.

  4. (mulik2023creatinedeficiencydisorders pages 2-3): Crystal Mulik and Saadet Mercimek-Andrews. Creatine deficiency disorders: phenotypes, genotypes, diagnosis, and treatment outcomes. Turkish Archives of Pediatrics, 58:129-135, Mar 2023. URL: https://doi.org/10.5152/turkarchpediatr.2023.23022, doi:10.5152/turkarchpediatr.2023.23022. This article has 11 citations.

  5. (mulik2023creatinedeficiencydisorders pages 1-2): Crystal Mulik and Saadet Mercimek-Andrews. Creatine deficiency disorders: phenotypes, genotypes, diagnosis, and treatment outcomes. Turkish Archives of Pediatrics, 58:129-135, Mar 2023. URL: https://doi.org/10.5152/turkarchpediatr.2023.23022, doi:10.5152/turkarchpediatr.2023.23022. This article has 11 citations.

  6. (marten2024longtermfollowup pages 1-2): Lara M. Marten, Ralph Krätzner, Gajja S. Salomons, Matilde Fernandez Ojeda, Peter Dechent, Jutta Gärtner, Peter Huppke, and Steffi Dreha-Kulaczewski. Long term follow-up in gamt deficiency – correlation of therapy regimen, biochemical and in vivo brain proton mr spectroscopy data. Molecular Genetics and Metabolism Reports, 38:101053, Mar 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101053, doi:10.1016/j.ymgmr.2024.101053. This article has 7 citations.

  7. (khoja2022genetherapyfor pages 1-2): Suhail Khoja, Jenna Lambert, Matthew Nitzahn, Adam Eliav, YuChen Zhang, Mikayla Tamboline, Colleen T. Le, Eram Nasser, Yunfeng Li, Puja Patel, Irina Zhuravka, Lindsay M. Lueptow, Ilona Tkachyova, Shili Xu, Itzhak Nissim, Andreas Schulze, and Gerald S. Lipshutz. Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities. Molecular Therapy - Methods & Clinical Development, 25:278-296, Jun 2022. URL: https://doi.org/10.1016/j.omtm.2022.03.015, doi:10.1016/j.omtm.2022.03.015. This article has 15 citations.

  8. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2): Sylvia Stockler-Ipsiroglu, Clara van Karnebeek, Nicola Longo, G. Christoph Korenke, Saadet Mercimek-Mahmutoglu, Iris Marquart, Bruce Barshop, Christiane Grolik, Andrea Schlune, Brad Angle, Helena Caldeira Araújo, Turgay Coskun, Luisa Diogo, Michael Geraghty, Goknur Haliloglu, Vassiliki Konstantopoulou, Vincenzo Leuzzi, Alina Levtova, Jennifer MacKenzie, Bruno Maranda, Aizeddin A. Mhanni, Grant Mitchell, Andrew Morris, Theresa Newlove, Deborah Renaud, Fernando Scaglia, Vassili Valayannopoulos, Francjan J. van Spronsen, Krijn T. Verbruggen, Nataliya Yuskiv, William Nyhan, and Andreas Schulze. Guanidinoacetate methyltransferase (gamt) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Molecular genetics and metabolism, 111 1:16-25, Jan 2014. URL: https://doi.org/10.1016/j.ymgme.2013.10.018, doi:10.1016/j.ymgme.2013.10.018. This article has 163 citations and is from a peer-reviewed journal.

  9. (ream2023evidenceandrecommendation pages 3-4): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.

  10. (marten2024longtermfollowup pages 7-7): Lara M. Marten, Ralph Krätzner, Gajja S. Salomons, Matilde Fernandez Ojeda, Peter Dechent, Jutta Gärtner, Peter Huppke, and Steffi Dreha-Kulaczewski. Long term follow-up in gamt deficiency – correlation of therapy regimen, biochemical and in vivo brain proton mr spectroscopy data. Molecular Genetics and Metabolism Reports, 38:101053, Mar 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101053, doi:10.1016/j.ymgmr.2024.101053. This article has 7 citations.

  11. (marten2024longtermfollowup pages 2-4): Lara M. Marten, Ralph Krätzner, Gajja S. Salomons, Matilde Fernandez Ojeda, Peter Dechent, Jutta Gärtner, Peter Huppke, and Steffi Dreha-Kulaczewski. Long term follow-up in gamt deficiency – correlation of therapy regimen, biochemical and in vivo brain proton mr spectroscopy data. Molecular Genetics and Metabolism Reports, 38:101053, Mar 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101053, doi:10.1016/j.ymgmr.2024.101053. This article has 7 citations.

  12. (ream2023evidenceandrecommendation pages 4-6): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.

  13. (ream2023evidenceandrecommendation media 0689e046): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.